mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis

GLIA

Volumn 61, Issue 3, 2013, Pages 301-311

  Dello Russo, Cinzia ^a   Lisi, Lucia ^a   Feinstein, Douglas L ^b   Navarra, Pierluigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Astrocytes; EAE; Inflammation; Microglia; MTOR; Multiple sclerosis; Myelination; Neuroprotection; NOS2; Oligodendrocytes; Peripheral immune system; T cells

Indexed keywords

CALCITRIOL; CYCLOSPORIN; FK 506 BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 MONOCLONAL ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; MONOCLONAL ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[35-55]; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL PROLIFERATION; CELL THERAPY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; DRUG POTENTIATION; EFFECTOR CELL; GLIA; GLIA CELL THERAPY; GRAFT REJECTION; HUMAN; HYPERALGESIA; IMMUNE SYSTEM; INNATE IMMUNITY; MICROGLIA; MULTIPLE SCLEROSIS; MYELINATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; RETINA NERVE CELL; RNA DEGRADATION; RNA TRANSCRIPTION; RNA TRANSLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH17 CELL;

AUTOPHAGY; CELL CYCLE; CELL PROLIFERATION; HUMANS; MULTIPLE SCLEROSIS; NEUROGLIA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84872609730     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22433     Document Type: Article

References (112)

1. Abe N, Borson SH, Gambello MJ, Wang F, Cavalli V. 2010. Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. J Biol Chem 285: 28034-28043.
2. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460: 108-112.
3. Berard JL, Wolak K, Fournier S, David S. 2010. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58: 434-445.
4. Bestard O, Cruzado JM, Grinyò JM. 2005. Calcineurin-inhibitor-sparing immunosuppressive protocols. Transplant Proc 37: 3729-3732.
5. Bibollet-Bahena O, Almazan G. 2009. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J Neurochem 109: 1440-1451.
6. Boer K, Troost D, Timmermans W, Gorter JA, Spliet WG, Nellist M, Jansen F, Aronica E. 2008. Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Neuroscience 156: 203-215.
7. Branisteanu DD, Mathieu C, Bouillon R. 1997. Synergism between sirolimus and 1, 25-dihydroxyvitamin D3 in vitro and in vivo. J Neuroimmunol 79: 138-147.
8. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. 2010. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. JBiol Chem 285: 13107-13120.
9. Campbell DS, Holt CE. 2001. Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation. Neuron 32: 1013-1026.
10. Carroll M, Dyer J, Sossin WS. 2006. Serotonin increases phosphorylation of synaptic 4EBP through TOR, but eukaryotic initiation factor 4E levels do not limit somatic cap-dependent translation in aplysia neurons. Mol Cell Biol 26: 8586-8598.
11. Chenal J, Pellerin L. 2007. Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway. J Neurochem 102: 389-397.
12. Chi H. 2012. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 12: 325-338.
13. Chong ZZ, Li F, Maiese K. 2007. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 19: 263-272.
14. Christie KJ, Webber CA, Martinez JA, Singh B, Zochodne DW. 2010 PTEN inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons. J Neurosci 30: 9306-9315.
15. Codeluppi S, Svensson CI, Hefferan MP, Valencia F, Silldorff MD, Oshiro M, Marsala M, Pasquale EB. 2009. The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord. J Neurosci 29: 1093-1104.
16. De Oliveira AC, Candelario-Jalil E, Langbein J, Wendeburg L, Bhatia HS, Schlachetzki JC, Biber K, Fiebich BL. 2012. Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation 9: 2.
17. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832-844.
18. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF, Powell JD. 2011. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 12: 295-303.
19. Dello Russo C, Lisi L, Tringali G, Navarra P. 2009. Involvement of mTOR kinase incytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol 78: 1242-1251.
20. Dennis PB, Fumagalli S, Thomas G. 1999. Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev 9: 49-54.
21. Donia M, Mangano K, Amoroso A, Mazzarino MC, Imbesi R, Castrogiovanni P, Coco M, Meroni P, Nicoletti F. 2009. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J Autoimmun 33: 135-140.
22. Dugas JC, Tai YC, Speed TP, Ngai J, Barres BA. 2006. Functional genomic analysis of oligodendrocyte differentiation. J Neurosci 26: 10967-10983.
23. Dunlop EA, Tee AR. 2009. Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. Cell Signal 21: 827-835.
24. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R. 2007. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis 26: 86-93.
25. Esposito M, Ruffini F, Bellone M, Gagliani N, Battaglia M, Martino G, Furlan R. 2010. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J Neuroimmunol 220: 52-63.
26. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. 2002. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 51: 694-702.
27. Fischer R, Turnquist HR, Taner T, Thomson AW. 2009. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol 188: 215-232.
28. Fitzner D, Simons M. 2010. Chronic progressive multiple sclerosis-pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol 8: 305-315.
29. Flores AI, Narayanan SP, Morse EN, Shick HE, Yin X, Kidd G, Avila RL, Kirschner DA, Macklin WB. 2008. Constitutively active Akt induces enhanced myelination in the CNS. J Neurosci 28: 7174-7183.
30. Foster KG, Fingar DC. 2010. Mammalian target of rapamycin (mTOR): Conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077.
31. Galea E, Heneka MT, Dello Russo C, Feinstein DL. 2003. Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol 23: 625-635.
32. Game DS, Hernandez-Fuentes MP, Lechler RI. 2005. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 5: 454-464.
33. Garelick MG, Kennedy BK. 2011. TOR on the brain. Exp Gerontol 46: 155-163.
34. Ghezzi A. 2004. Clinical characteristics of multiple sclerosis with early onset. Neurol Sci 25 (Suppl 4): S336-S339.
35. Goebbels S, Oltrogge JH, Kemper R, Heilmann I, Bormuth I, Wolfer S, Wichert SP, Möbius W, Liu X, Lappe-Siefke C, Rossner MJ, Groszer M, Suter U, Frahm J, Boretius S, Nave KA. 2010. Elevated phosphatidylinositol 3, 4, 5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J Neurosci 30: 8953-8964.
36. Griffin WS. 2006. Inflammation and neurodegenerative diseases. Am J Clin Nutr 83: 470S-474S.
37. Guardiola-Diaz HM, Ishii A, Bansal R. 2012. Erk1/2 MAPK and mTOR signalling sequentially regulates progression through distinct stages of oligodendrocyte differentiation. Glia 60: 476-486.
38. Guertin DA, Steven DM, Thoreen CC, Burds AA, Kalaa NY, Moffat J, Brawn M, Fitzgerald KJ, Sabatini DM. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signalign to Akt-Foxo and PKCalpha but not S6K1. Dev Cells 11: 859-871.
39. Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD Tuohy VK, Cua DJ, Li X. 2010. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 32: 54-66.
40. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. 2002. Raptor, a binding partner of target of Rapamycin (TOR), mediates TOR action. Cell 110: 177-189.
41. Hartford CM, Ratain MJ. 2007. Rapamycin: Something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther 82: 381-388.
42. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, Korosec T, Kutzelnigg A, Berger JJ, Bradl M, Bittner RE, Lassmann H. 2006. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 65: 855-865.
43. Hoeffer CA, Klann E. 2010. mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 33: 67-75.
44. Hresko RC, Mueckler M. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406-40416.
45. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. 2001. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36: 220-234.
46. Inoki K. 2008. Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract 82 (Suppl 1): S59-S62.
47. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6: 1122-1128.
48. Jang BC, Paik JH, Kim SP, Shin DH, Song DK, Park JG, Suh MH, Park JW, Suh SI. 2005. Catalase induced expression of inflammatory mediators via activation of NF-kappaB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia. Cell Signal 17: 625-633.
49. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. 2005. Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 25: 11300-11312.
50. Jaworski J, Sheng M. 2006. The growing role of mTOR in neuronal development and plasticity. Mol Neurobiol 34: 205-219.
51. Jones JL, Coles AJ. 2010. New treatment strategies in multiple sclerosis. Exp Neurol 225: 34-39.
52. Jozwiak J, Jozwiak S, Oldak M. 2006. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev 26: 160-180.
53. Juedes AE, Hjelmström P, Bergman CM, Neild AL, Ruddle NH. 2000. Kinetics and cellular origin of cytokines in the central nervous system: Insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol 164: 419-426.
54. Kelly PA, Gruber SA, Behbod F, Kahan BD. 1997. Sirolimus, a new potent immunosuppressive agent. Pharmacotherapy 17: 1148-1156.
55. Kim DH, Sarbassoy DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175.
56. Kim SR, Chen X, Oo TF, Kareva T, Yarygina O, Wang C, During M, Kholodilov N, Burke RE. 2011. Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol 70: 110-120.
57. Kindler S, Kreienkamp HJ. 2012. Dendritic mRNA targeting and translation. Adv Exp Med Biol 970: 285-305.
58. Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY. 2005. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 25: 11288-11299.
59. Kwiatkowski DJ. 2003. Tuberous sclerosis: From tubers to mTOR. Ann Hum Genet 67: 87-96.
60. Lassmann H. 2007. Experimental models of multiple sclerosis. Rev Neurol (Paris) 163: 651-655.
61. Lee CC, Huang CC, Hsu KS. 2011. Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology 61: 867-879.
62. Lenz G, Avruch J. 2005. Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. J Biol Chem 280: 38121-38124.
63. Lisi L, Navarra P, Feinstein DL, Dello Russo C. 2011. The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation 8: 1.
64. Lisi L, Navarra P, Cirocchi R, Sharp A, Stigliano E, Feinstein DL, Dello Russo C. 2012. Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis. J Neuroimmunol 243: 43-51.
65. Liu K, Lu Y, Lee JK, Samara R, Willenberg R, Sears-Kraxberger I, Tedeschi A, Park KK, Jin D, Cai B, Xu B, Connolly L, Steward O, Zheng B, He Z. 2010. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci 13: 1075-1081.
66. Lu DY, Liou HC, Tang CH, Fu WM. 2006. Hypoxia-induced iNOS expression in microgliais regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1alpha. Biochem Pharmacol. 72: 992-1000.
67. Ma XM, Blenis J. 2009. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
68. Martel RR, Klicius J, Galet S. 1977. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55: 48-51.
69. Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. 2008. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 28: 5422-5432.
70. Mondino A, Mueller DL. 2007. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 19: 162-172.
71. Monti P, Mercalli A, Leone BE, Valerio DC, Allavena P, Piemonti L. 2003. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 75: 137-145.
72. Narayanan SP, Flores AI, Wang F, Macklin WB. 2009. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 29: 6860-6870.
73. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343: 938-952.
74. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. 2008. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 137: 96-111.
75. Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan M, Roux PP, Su B, Jacinto E. 2010. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J 29: 3939-3951.
76. Okada K, Tanaka H, Temporin K, Okamoto M, Kuroda Y, Moritomo H, Murase T, Yoshikawa H. 2011. Akt/mammalian target of rapamycin signaling pathway regulates neurite outgrowth in cerebellar granule neurons stimulated by methylcobalamin. Neurosci Lett 495: 201-204.
77. Park J, Zhang J, Qiu J, Zhu X, Degterev A, Lo EH, Whalen MJ. 2012. Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab 32: 330-340.
78. Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M, He Z. 2008. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 322: 963-966.
79. Pastor MD, Garcìa-Yébenes I, Fradejas N, Pérez-Ortiz JM, Mora-Lee S, Tranque P, Moro MA, Pende M, Calvo S. 2009. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. J Biol Chem 284: 22067-22078.
80. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886.
81. Pong K, Zaleska MM. 2003. Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord 2: 349-356.
82. Powell JD, Delgoffe GM. 2010. The mammalian target of rapamycin: Linking T cell differentiation, function, and metabolism. Immunity 33: 301-311.
83. Procaccini C, De Rosa V, Galgani M, Abanni L, Calì G, Porcellini A, Carbone F, Fontana S, Horvath TL, La Cava A, Matarese G. 2010. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 33: 929-941.
84. Proud CG. 2007 Cell signaling. mTOR, unleashed. Science 318: 926-927.
85. Quevedo C, Salinas M, Alcázar A. 2002. Regulation of cap-dependent translation by insulin-like growth factor-1 in neuronal cells. Biochem Biophys Res Commun 291: 560-566.
86. Rangaraju S, Verrier JD, Madorsky I, Nicks J, Dunn WA Jr, Notterpek L. 2010. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci 30: 11388-11397.
87. Sansal I, Sellers WR. 2004. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963.
88. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302.
89. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
90. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
91. Schmitz F, Heit A, Dreher S, Eisenächer K, Mages J, Haas T, Krug A, Janssen KP, Kirschning CJ, Wagner H. 2008. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 38: 2981-2992.
92. Shang YC, Chong ZZ, Wang S, Maiese K. 2011. Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res 8: 270-285.
93. Shi LZ, Wang R, Huang G, Vogel P, Neale G, Green DR, Chi H. 2011. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med 208: 1367-1376.
94. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V. 2010. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 5: 1-8.
95. Takei N, Kawamura M, Ishizuka Y, Kakiya N, Inamura N, Namba H, Nawa H. 2009. Brain-derived neurotrophic factor enhances the basal rate of protein synthesis by increasing active eukaryotic elongation factor 2 levels and promoting translation elongation in cortical neurons. J Biol Chem 284: 26340-26348.
96. Tan YV, Abad C, Lopez R, Dong H, Liu S, Lee A, Gomariz RP, Leceta J, Waschek JA. 2009. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 106: 2012-2017.
97. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. 2002. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A 99: 467-472.
98. Thomson AW, Turnquist HR, Raimondi G. 2009 Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9: 324-337.
99. Thoreen CC, Sabatini DM. 2009. Rapamycin inhibits mTORC1, but not completely. Autophagy 5: 725-726.
100. Tsang CK, Qi H, Liu LF, Zheng XF. 2007. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12: 112-124.
101. Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW, Wood TL. 2009. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 29: 6367-6378.
102. Tyler WA, Jain MR, Cifelli SE, Li Q, Ku L, Feng Y, Li H, Wood TL. 2011. Proteomic identification of novel targets regulated by the mammalian target of rapamycin pathway during oligodendrocyte differentiation. Glia 59: 1754-1769.
103. van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C. 2000. Analogs of 1, 25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 69: 1932-1942.
104. Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, Grey ST. Sprent J. 2009. In vivo expansion of T reg cells with IL-2-mAb complexes: Induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 206: 751-760.
105. Weichhart T, Säemann MD. 2008. The PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann Rheum Dis 67: 70-74.
106. Weichhart T, Säemann MD. 2009. The multiple facets of mTOR in immunity. Trends Immunol 30: 218-226.
107. Weinstein SL, Finn AJ, Davé SH, Meng F, Lowell CA, Sanghera JS, DeFranco AL. 2000. Phosphatidylinositol 3-kinase and mTOR mediate lipopolysaccharide-stimulated nitric oxide production in macrophages via interferon-beta. J Leukoc Biol 67: 405-414.
108. Wu X, Reiter CE, Antonetti DA, Kimball SR, Jefferson LS, Gardner TW. 2004. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. J Biol Chem 279: 9167-9175.
109. Wu X, Kihara T, Akaike A, Niidome T, Sugimoto H. 2010. PI3K/Akt/mTOR signalling regulates glutamate transporter 1 in astrocytes. Biochem Biophys Res Commun 393: 514-518.
110. Wullschleger S, Loewith R, Hall MN. 2006. TOR signaling in growth and metabolism. Cell 124: 471-484.
111. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. 2010. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 38: 768-774.
112. Zhong XP, Shin J, Gorentla BK, O'Brien T, Srivatsan S, Xu L, Chen Y, Xie D, Pan H. 2010 Receptor signaling in immune cell development and function. Immunol Res 49: 109-123.